Today, the CEO of Plus Therapeutics (PSTV), Marc Hedrick, bought shares of PSTV for $4,975.
This recent transaction increases Marc Hedrick’s holding in the company by 21.99% to a total of $28.43K.
See today’s analyst top recommended stocks >>
Currently, Plus Therapeutics has an average volume of 321.78K. PSTV’s market cap is $9.8 million and the company has a P/E ratio of 0.20. The company has a one-year high of $3.56 and a one-year low of $0.93.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
